183 related articles for article (PubMed ID: 16213594)
1. MAOI efficacy and safety in advanced stage treatment-resistant depression--a retrospective study.
Amsterdam JD; Shults J
J Affect Disord; 2005 Dec; 89(1-3):183-8. PubMed ID: 16213594
[TBL] [Abstract][Full Text] [Related]
2. Relative effectiveness of tricyclic antidepressant versus monoamine oxidase inhibitor monotherapy for treatment-resistant depression.
Kim T; Xu C; Amsterdam JD
J Affect Disord; 2019 May; 250():199-203. PubMed ID: 30861462
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
4. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial.
Amsterdam JD; Bodkin JA
J Clin Psychopharmacol; 2006 Dec; 26(6):579-86. PubMed ID: 17110814
[TBL] [Abstract][Full Text] [Related]
5. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.
Henkel V; Seemüller F; Obermeier M; Adli M; Bauer M; Mundt C; Brieger P; Laux G; Bender W; Heuser I; Zeiler J; Gaebel W; Mayr A; Möller HJ; Riedel M
J Affect Disord; 2009 Jun; 115(3):439-49. PubMed ID: 19027961
[TBL] [Abstract][Full Text] [Related]
6. The combination of duloxetine and bupropion for treatment-resistant major depressive disorder.
Papakostas GI; Worthington JJ; Iosifescu DV; Kinrys G; Burns AM; Fisher LB; Homberger CH; Mischoulon D; Fava M
Depress Anxiety; 2006; 23(3):178-81. PubMed ID: 16528701
[TBL] [Abstract][Full Text] [Related]
7. Current prescription patterns and safety profile of irreversible monoamine oxidase inhibitors: a population-based cohort study of older adults.
Shulman KI; Fischer HD; Herrmann N; Huo CY; Anderson GM; Rochon PA
J Clin Psychiatry; 2009 Dec; 70(12):1681-6. PubMed ID: 19852903
[TBL] [Abstract][Full Text] [Related]
8. Cost burden of treatment resistance in patients with depression.
Gibson TB; Jing Y; Smith Carls G; Kim E; Bagalman JE; Burton WN; Tran QV; Pikalov A; Goetzel RZ
Am J Manag Care; 2010 May; 16(5):370-7. PubMed ID: 20469957
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression.
Thomas SJ; Shin M; McInnis MG; Bostwick JR
Pharmacotherapy; 2015 Apr; 35(4):433-49. PubMed ID: 25884531
[TBL] [Abstract][Full Text] [Related]
11. Open-label study of s-citalopram therapy of chronic fatigue syndrome and co-morbid major depressive disorder.
Amsterdam JD; Shults J; Rutherford N
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):100-6. PubMed ID: 17804135
[TBL] [Abstract][Full Text] [Related]
12. Safety of high-intensity treatment with the irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistant depression.
Adli M; Pilhatsch M; Bauer M; Köberle U; Ricken R; Janssen G; Ulrich S; Bschor T
Pharmacopsychiatry; 2008 Nov; 41(6):252-7. PubMed ID: 19067263
[TBL] [Abstract][Full Text] [Related]
13. Polypharmacy prevalence rates in the treatment of unipolar depression in an outpatient clinic.
Glezer A; Byatt N; Cook R; Rothschild AJ
J Affect Disord; 2009 Sep; 117(1-2):18-23. PubMed ID: 19103462
[TBL] [Abstract][Full Text] [Related]
14. Impacts of switching antidepressants after successful electroconvulsive therapy on the maintenance of clinical remission in patients with treatment-resistant depression: a chart review.
Nakajima S; Ishida T; Akaishi R; Takahata K; Kitahata R; Uchida H; Suzuki T; Takeuchi H; Nomura K; Nakagawa A; Watanabe K; Kashima H
J ECT; 2009 Sep; 25(3):178-81. PubMed ID: 19710625
[TBL] [Abstract][Full Text] [Related]
15. Does tachyphylaxis occur after repeated antidepressant exposure in patients with Bipolar II major depressive episode?
Amsterdam JD; Shults J
J Affect Disord; 2009 May; 115(1-2):234-40. PubMed ID: 18694599
[TBL] [Abstract][Full Text] [Related]
16. Serious life events among resistant and non-resistant MDD patients.
Amital D; Fostick L; Silberman A; Beckman M; Spivak B
J Affect Disord; 2008 Oct; 110(3):260-4. PubMed ID: 18262654
[TBL] [Abstract][Full Text] [Related]
17. Reboxetine addition in patients with mirtazapine-resistant depression: a case series.
López-Muñoz F; Rubio G; Alamo C; García-García P; Pardo A
Clin Neuropharmacol; 2006; 29(4):192-6. PubMed ID: 16855420
[TBL] [Abstract][Full Text] [Related]
18. Treatment-resistant depression.
Souery D; Papakostas GI; Trivedi MH
J Clin Psychiatry; 2006; 67 Suppl 6():16-22. PubMed ID: 16848672
[TBL] [Abstract][Full Text] [Related]
19. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
[TBL] [Abstract][Full Text] [Related]
20. Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after recovery from an acute episode of moderate depression--a double-blind, randomized, placebo controlled long-term trial.
Kasper S; Volz HP; Möller HJ; Dienel A; Kieser M
Eur Neuropsychopharmacol; 2008 Nov; 18(11):803-13. PubMed ID: 18694635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
